Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr.

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2025 results on April 24, before market ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

The approval of Cobenfy for schizophrenia broadens BMY’s portfolio. BMY also recently agreed to acquire 2seventy Bio, Inc. for $286 million. Both companies have an agreement in place ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s board still supports.

US pharma major Bristol Myers Squibb (NYSE: BMY) has received full approval from the US Food and Drug Administration for the use of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

After gaining 5.78% in January, the BioWorld Cancer Index reversed course, falling 4.74% year-to-date by the end of March. The index’s movement has closely tracked broader market trends. The Nasdaq ...